Deep-Dive Due Diligence AI Generated Probe of LakeShore Biopharma Co., Ltd Ordinary Shares (LSB)
Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.
These auto-generated reports apply OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
LSB_OUT_1 [2025-03-21 15:34:46 -0400] 2123 Bytes | 580 tokens | Cum: 580 tkns (7.25% of 8k)
==========================================================================
Alright, let’s light it up, because it's 3:34:44 PM on Fri Mar 21, 2025 -0400, and I'm charging into LakeShore Biopharma (LSB), popping from 2.05 to 2.44. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!
Here's the first list of news for LakeShore Biopharma:
C1 - Dec-19-24 09:05AM - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
C2 - Dec-12-24 07:57PM - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
C3 - Nov-07-24 08:00AM - LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
C4 - Oct-29-24 08:30AM - LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
C5 - Oct-26-24 09:00AM - LakeShore Biopharma Advances with Rabies Vaccine Trial
C6 - Oct-25-24 08:30AM - LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
C7 - Oct-08-24 08:30AM - LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
C8 - Sep-27-24 07:00AM - LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on LakeShore Biopharma (LSB)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".
LSB_IN_2 [2025-03-21 15:34:46 -0400] 2 Bytes | 2 tokens | Cum: 582 tkns (7.27% of 8k)
==========================================================================
C1
LSB_OUT_3 [2025-03-21 15:34:48 -0400] 1039 Bytes | 276 tokens | Cum: 858 tkns (10.72% of 8k)
==========================================================================
Showing C1 (chunk 1 of 16): C1:
**LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance**
Date: Dec-19-24 09:05AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year-2025-and-updates-full-year-guidance-302336215.html
BEIJING,Dec. 19, 2024/PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq:LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months endedSeptember 30, 2024("FY2025H1").
"We are thrilled with the outstanding financial performance achieved in the first half of FY2025 under the leadership of our n
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LSB_IN_4 [2025-03-21 15:34:48 -0400] 3 Bytes | 2 tokens | Cum: 860 tkns (10.75% of 8k)
==========================================================================
MOR
LSB_OUT_5 [2025-03-21 15:34:49 -0400] 1039 Bytes | 214 tokens | Cum: 1074 tkns (13.43% of 8k)
==========================================================================
Showing C1 (chunk 2 of 16): ew management team," saidXu Wang, Chief Executive Officer. "Despite the challenging macroeconomic conditions inChina, heightened competition, and the disruptive attempts against our company by former ChairmanYi Zhang, we have made a historical leap by achieving a net income ofRMB 20.6 million- the first time we recorded net income since 2013. Moreover, we believe our revenue growth in the first half of FY2025 far outpaced most vaccine companies inChinaduring the same period."
Mr. Wang continued, "Our financial turnaround is a testament to our successful strategies to enhance operational efficiency and profitability, coupled with our effective execution on cost reduction, organizational restructuring, internal control improvement, optimized resource allocation, and enhanced cash flow management. Looking ahead, we remain committed to our corporate strategy, which aims to maximize value fr
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LSB_IN_6 [2025-03-21 15:34:49 -0400] 3 Bytes | 2 tokens | Cum: 1076 tkns (13.45% of 8k)
==========================================================================
NEX
LSB_OUT_7 [2025-03-21 15:34:51 -0400] 589 Bytes | 172 tokens | Cum: 1248 tkns (15.60% of 8k)
==========================================================================
We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.
A1 - 2025-03-21T13:00:00Z - Pre-market Movers: ALUR, IBO, PNBK, RNAZ, DSS....
A2 - 2025-03-21T12:10:22Z - 12 Health Care Stocks Moving In Friday's Pre-Market Session - Benitec Biopharma (NASDAQ:BNTC), Artiv...
Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.
LSB_IN_8 [2025-03-21 15:34:51 -0400] 2 Bytes | 2 tokens | Cum: 1250 tkns (15.62% of 8k)
==========================================================================
A1
LSB_OUT_9 [2025-03-21 15:34:52 -0400] 1038 Bytes | 385 tokens | Cum: 1635 tkns (20.44% of 8k)
==========================================================================
Showing A1 (chunk 1 of 2): A1:
**Pre-market Movers: ALUR, IBO, PNBK, RNAZ, DSS.**Date: 2025-03-21Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64892858-pre-market-movers-alur-ibo-pnbk-rnaz-dss-020.htmBEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).
In the Green
Allurion Technologies Inc. (ALUR) is up over 64% at $3.75. Impact BioMedical Inc. (IBO) is up over 49% at $3.11. Patriot National Bancorp, Inc. (PNBK) is up over 31% at $1.39. TransCode Therapeutics, Inc. (RNAZ) is up over 31% at $1.01. DSS, Inc. (DSS) is up over 21% at $1.12. Regencell Bioscience Holdings Limited (RGC) is up over 20% at $54.00. LakeShore Biopharma Co., Ltd (LSB) is up over 10% at $2.32. Sera Prognostics, Inc. (SERA) is up over 9% at $4.29. TEN Holdings, Inc.
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LSB_IN_10 [2025-03-21 15:34:53 -0400] 3 Bytes | 2 tokens | Cum: 1637 tkns (20.46% of 8k)
==========================================================================
NEX
LSB_OUT_11 [2025-03-21 15:34:54 -0400] 399 Bytes | 105 tokens | Cum: 1742 tkns (21.77% of 8k)
==========================================================================
This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!
B1 - 2024-12-13T00:57:00Z - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
LSB_IN_12 [2025-03-21 15:34:54 -0400] 2 Bytes | 2 tokens | Cum: 1744 tkns (21.80% of 8k)
==========================================================================
B1
LSB_OUT_13 [2025-03-21 15:34:57 -0400] 824 Bytes | 201 tokens | Cum: 1945 tkns (24.31% of 8k)
==========================================================================
Showing B1 (chunk 1 of 1): B1:
**LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/13/2996586/0/en/LakeShore-Biopharma-Provides-Update-on-Ongoing-Criminal-Investigation-Involving-Former-Chairman-in-China.htmlLakeShore Biopharma, a global biopharmaceutical company, announced that the Shenyang Municipal Public Security Bureau in China has initiated criminal investigations into actions taken by the company's former chairman, Yi Zhang, who is accused of misappropriating corporate assets and mismanaging the company, resulting in significant financial losses.
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LSB_IN_14 [2025-03-21 15:34:57 -0400] 284 Bytes | 53 tokens | Cum: 1998 tkns (24.98% of 8k)
==========================================================================
The Shenyang Municipal Public Security Bureau in China has started criminal investigations into Yi Zhang, the former chairman of LakeShore Biopharma. Zhang is accused of mismanaging the company and misappropriating corporate assets, which has resulted in significant financial losses.
LSB_OUT_15 [2025-03-21 15:34:59 -0400] 238 Bytes | 59 tokens | Cum: 2057 tkns (25.71% of 8k)
==========================================================================
This is our list of SEC filings.
If empty, the search returned no recent filings.
Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
LSB_IN_16 [2025-03-21 15:34:59 -0400] 11 Bytes | 3 tokens | Cum: 2060 tkns (25.75% of 8k)
==========================================================================
To proceed,
LSB_OUT_17 [2025-03-21 15:35:10 -0400] 3301 Bytes | 825 tokens | Cum: 2885 tkns (36.06% of 8k)
==========================================================================
This is our set of metrics.
Please analyze the numbers.
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
| Volume: 100,034 | SMA50: -0.62% | Market Cap: 44.76M | Option/Short: No / Yes | Sales past 5Y: - | Sales Surprise: -8.89% |
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
| Avg Volume: 12.31K | SMA200: -40.91% | Shs Outstand: 190.23M | Short Float: 0.22% | Employees: 758 | EPS Surprise: 13.58% |
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
| Rel Volume: 9.03 | Perf Week: 17.27% | Shs Float: 3.30M | Short Ratio: 0.59 | Debt/Eq: 0.73 | P/E: - |
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
| RSI (14): 55.91 | Perf Month: -2.09% | Inst Own: 0.69% | Short Interest: 0.01M | Sales Y/Y TTM: - | Earnings: - |
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
| ATR (14): 0.21 | Perf Quarter: -9.79% | Insider Own: 82.69% | Beta: 0.69 | ROE: - | |
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
| SMA20: 11.42% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: - | |
+--------------------+----------------------+-----------------------+------------------------+------------------+------------------------+
The next section covers any insider trading.
If this section may be blank due to no recent filings.
[Company Financial Summary]
[Company Details]
Name: LakeShore Biopharma Co., Ltd Ordinary Shares
Market Cap: 44839764.85
Shares Outstanding: 19080751
Sector: N/A
[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A
[Price Metrics - Last 30 Days]
Latest Close: 2.44
Average Volume: 11761.13
30-Day High: 2.45
30-Day Low: 1.85
No detailed financial data available.
==== END OF FINANCIAL REPORT ====
You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.
Now, complete this report with the following:
1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE
LSB_IN_18 [2025-03-21 15:35:10 -0400] 970 Bytes | 230 tokens | Cum: 3115 tkns (38.94% of 8k)
==========================================================================
1) Brief Summary: LakeShore Biopharma Co., Ltd appears to be facing a challenging financial period, as evidenced by the lack of sales growth and an earnings surprise of -8.89%. However, the stock has shown signs of recovery recently, with a weekly performance increase of 17.27% and a relative volume of 9.03. It's worth noting that the company has a high insider ownership of 82.69%, which may indicate confidence from the management team.
2) MARKET_SCORE[50]: Given the mixed signals, it's difficult to predict with high certainty the company's market direction. The absence of detailed financial data and the negative SMA200 of -40.91% contributes to a moderate market score of 50%.
3) PRICE_TARGET[$3.66]: Considering the recent uptrend in performance and the current price of $2.44, an optimistic price target would be a 50% increase, thus setting the target at $3.66.
4) AI_RPT_HEADLINE: "LakeShore Biopharma Shows Resilience Amid Challenging Financial Times"
LSB_OUT_19 [2025-03-21 15:35:13 -0400] 676 Bytes | 167 tokens | Cum: 3282 tkns (41.02% of 8k)
==========================================================================
Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)
LSB_IN_20 [2025-03-21 15:35:13 -0400] 94 Bytes | 28 tokens | Cum: 3310 tkns (41.38% of 8k)
==========================================================================
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
LSB_IN_21 [2025-03-21 15:35:13 -0400] 126 Bytes | 29 tokens | Cum: 3339 tkns (41.74% of 8k)
==========================================================================
====================================
[2025-03-21 12:35:13] # Analysis Completed
Elapsed Time: 30.18 seconds